<DOC>
	<DOCNO>NCT02448719</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability profile TAK-792 administer single oral dose healthy Japanese Caucasian male participant .</brief_summary>
	<brief_title>Single-Dose Phase 1 Study TAK-792</brief_title>
	<detailed_description>This study double-blind placebo-controlled avoid subjective bias assessment safety tolerability TAK-792 . Sentinel dose use first cohort ( cohort 1 ) ensure adequate safety tolerability evaluation prior administer TAK-792 remainder participant within cohort . The dose escalation next cohort Cohorts 2 6 occur full review safety tolerability current cohort , available pharmacokinetic data 24 hr precede cohort . The plan dose level 30 , 100 , 250 , 500 , 750 1250 mg , administer morning fast least 10 hour .</detailed_description>
	<criteria>1 . In opinion investigator subinvestigator , , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form require privacy authorization prior initiation study procedures 3 . The participant healthy male Japanese descent ( bear Japanese parent grandparent ) Caucasian descent ( born Caucasian parent grandparent ) . 4 . The participant age 20 45 year , inclusive , time informed consent . 5 . The participant weighs least 50 kg body mass index ( BMI ) 18.5kg/m2 25.0 kg/m2 Japanese , BMI 18.5 kg/m2 30.0 kg/m2 Caucasian , inclusive Screening Day 1 . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . . 1 . The participant receive investigational compound within 16 week ( 112 day ) prior dose study medication . 2 . The participant immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 3 . The participant uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urological , endocrine disease abnormality , may impact ability participant participate potentially confound study result . 4 . The participant positive urine drug result drug abuse Screening . 5 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 6 . Participant take excluded medication , supplement , food product list Excluded Medications Dietary Products table . 7 . The participant intend donate sperm course study 12 week thereafter . . 8 . Participant evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . 9 . Participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis frequent [ per week ] occurrence heartburn , surgical intervention [ eg , cholecystectomy ] ) . 10 . Participant history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 11 . Participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , human immunodeficiency virus ( HIV ) antibody { /antigen } , serological reaction syphilis Screening . 12 . Participant use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin Day 1 . Cotinine test positive Screening . 13 . The participant poor peripheral venous access . 14 . The participant undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior start study drug administration . 15 . The participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior start study drug administration . 16 . The participant undergone blood component collection within 2 week ( 14 day ) prior start study drug administration . 17 . Participant Screening abnormal ( clinically significant ) ECG . 18 . Participant abnormal Screening laboratory value suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 upper limit normal . 19 . Participant , opinion investigator subinvestigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>